Do the European League Against Rheumatism (EULAR) Sjögren’s syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren’s syndrome?

Omma, Ahmet; Tecer, Duygu; Küçükşahin, Orhan; Sandıkçı, Sevinç Can; Yıldız, Fatih; Erten, Şükran

doi:10.5114/aoms.2017.70300

Cited by 15 publications

(18 citation statements)

References 39 publications

(49 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of SS was captured on the provider form and is considered a critical field of data for Corrona. The results from this observational study in US patients complement previous studies [8,9,19,[21][22][23].…”

Section: Discussionsupporting

confidence: 88%

“…Patients with RA and SS were also more likely to have co-morbidities and to be taking several treatments for RA. These results complement published data examining the effect of SS on quality of life [8,19]. The symptoms of SS exert a burden on a patient that may impact physical and social functioning, which in turn may affect employment status.…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

Harrold

Shan²,

Rebello³

et al. 2020

Rheumatol Int

View full text Add to dashboard Cite

The objective of this study was to compare rheumatoid arthritis (RA) disease activity and patient-reported outcomes (PROs) in a national sample of patients with RA with/without Sjögren's syndrome (SS). Adults with RA from a large observational US registry (Corrona RA) with known SS status between 22 April 2010 and 31 July 2018 and a visit 12 (± 3) months after index date were identified (n = 36,256/52,757). SS status: determined from a yes/no variable reported at enrolment into the Corrona RA registry and follow-up visits. Index date: date that SS status was recorded (yes/no). Patients received biologic or targeted synthetic disease-modifying antirheumatic drugs as part of standard care. Patients with RA only were followed for ≥ 12 months to confirm the absence of SS. Patients were frequency-and propensity-score matched (PSM) 1:1 and stratified by disease duration and treatment response-associated variables, respectively. Clinical Disease Activity Index (CDAI) and PROs 12 months after index visit were compared in patients with and without SS. Baseline characteristics in 283 pairs of PSM patients were balanced. Mean change in CDAI score was numerically lower in patients with RA and SS than patients with RA only (8.8 vs 9.3). Reductions in PROs of pain, fatigue and stiffness were two-to threefold lower for patients with RA and SS versus RA only. Reductions in RA disease activity and RA-related PROs were lower in patients with RA and SS versus those with RA only. Our data indicate that SS adds to treatment challenges; physicians may wish to consider SS status when managing patients with RA.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionsupporting

confidence: 82%

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

Harrold

Shan²,

Rebello³

et al. 2020

Rheumatol Int

View full text Add to dashboard Cite

show abstract

“…A strong correlation was observed between the presence of subjective cognitive symptoms and fatigue severity, and dysfunction in attention, executive functions, working memory, and verbal memory among objective cognitive tests [45]. Among the studies included in this review, eight also had assessed fatigue [20,22,28,29,30,33,34,36]. The case-control study published in 2016 by Kocer et al was of great interest; 32 patients with pSS were evaluated through comprehensive neuropsychological tests and neuroimaging.…”

Section: Resultsmentioning

confidence: 99%

Cognitive Function in Primary Sjögren’s Syndrome: A Systematic Review

et al. 2019

View full text Add to dashboard Cite

Background: Cognitive disorders are reported to be common in patients with primary Sjogren’s syndrome (pSS). In some cases, they are the first clinical manifestation, preceding the diagnosis of pSS by two years on average. Aim: A systematic review was conducted to explore cognitive impairment in pSS, with reference to diagnostic methods and their relationship with laboratory data and clinical manifestations. Materials and Methods: According to the PRISMA 2009 checklist, we carried out a comprehensive literature search in the three main bibliographic databases: MEDLINE, EMBASE, and PsycINFO (NICE HDAS interface). The following main search terms were used: primary Sjogren syndrome, neurological manifestations, fatigue, cognitive functions, psychiatric manifestations, mild cognitive impairment, dementia, and neurocognitive disorder. The search was made on 14 September, 2018. References from all selected studies were also examined. Inclusion criteria were: all studies and case-reports published in any language from 2002 that assessed the association of pSS (according to classification criteria proposed by the 2002 American/European collaborative group (AECG)) with all types of cognitive impairment (including dementia). Exclusion criteria were: reviews, abstracts, secondary Sjögren’s syndrome (SS), and all articles in which other classification criteria were used. Results: The initial search yielded 352 articles, of which 253 were excluded based on the title and abstract review. A total of 54 articles underwent a full-length review, and 32 articles were excluded. Data were extracted from 18 studies and three case-reports involving a total of 6196 participants. In most cases, cognitive dysfunction was a brain fog or a mild cognitive impairment (MCI). Occasionally, an autoimmune dementia was present. The relationship between pSS and degenerative dementias, such as Alzheimer’s disease (AD), was a controversial issue, even if some investigators hypothesized that pSS could be a risk factor. Several unmet needs were highlighted. First, some of the included studies had not reported the severity of pSS; hence, few correlations between disease severity and cognitive function were possible. Secondly, the evaluation of the pathogenetic role of comorbid diseases was often absent. The lack of information on the type of dementia represented a third critical point in the majority of the included studies. Conclusions: This systematic review confirmed that adequate studies on cognitive function in pSS are scarce, mostly performed on small-sized samples, and often conflicting. The routine assessment of cognitive function in patients with pSS seems advisable and it will help to elucidate some of the unmet needs highlighted by this review in future appropriately designed studies.

show abstract

“…Making use of the progressive implementation of the CIPA screening in a centre, we performed a study that compared the application of the screen-ing tool with standard clinical practice and evaluated its cost-effectiveness, as well as other clinical outcomes [16,17]. The importance of this work lies in that, to our knowledge, this is the first study to thoroughly evaluate these aspects after implementing a hospital nutrition screening programme.…”

Section: Introductionmentioning

confidence: 99%

Cost-effectiveness of the hospital nutrition screening tool CIPA

Llanos

Vallejo-Torres

García‐Bello

et al. 2020

aoms

View full text Add to dashboard Cite

A b s t r a c t Introduction: Hospital malnutrition is very common and worsens the clinical course of patients while increasing costs. Lacking clinical-economic studies on the implementation of nutrition screening encouraged the evaluation of the CIPA (Control of Food Intake, Protein, Anthropometry) tool. Material and methods: An open, non-randomized, controlled clinical trial was conducted on patients admitted to internal medicine and general and digestive surgery wards, who were either assigned to a control (standard hospital clinical care) or to an intervention, CIPA-performing ward (412 and 411, respectively; n = 823). Length of stay, mortality, readmission, in-hospital complications, and quality of life were evaluated. Cost-effectiveness was analysed in terms of cost per quality-adjusted life years (QALYs). Results: The mean length of stay was higher in the CIPA group, though not significantly (+ 0.95 days; p = 0.230). On the surgical ward, more patients from the control group moved to critical care units (p = 0.014); the other clinical variables did not vary. Quality of life at discharge was similar (p = 0.53), although slightly higher in the CIPA group at 3 months (p = 0.089). Patients under CIPA screening had a higher mean cost of € 691.6 and a mean QALY gain over a 3-month period of 0.0042. While the cost per QALY for the internal medicine patients was € 642 282, the results for surgical patients suggest that the screening tool is both less costly and more effective. Conclusions: The CIPA nutrition screening tool is likely to be cost-effective in surgical but not in internal medicine patients.

show abstract

Do the European League Against Rheumatism (EULAR) Sjögren’s syndrome outcome measures correlate with impaired quality of life, fatigue, anxiety and depression in primary Sjögren’s syndrome?

Cited by 15 publications

References 39 publications

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

Disease activity and patient-reported outcomes in patients with rheumatoid arthritis and Sjögren’s syndrome enrolled in a large observational US registry

Cognitive Function in Primary Sjögren’s Syndrome: A Systematic Review

Cost-effectiveness of the hospital nutrition screening tool CIPA

Contact Info

Product

Resources

About